Castleark Management’s Neurocrine Biosciences NBIX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-53,600	Closed	-$6.4M	–	309
2022 Q4	$6.4M	Buy	53,600 +830	+2%	+$97.2K	0.33%	71
2022 Q3	$5.61M	Sell	52,770 -1,230	-2%	-$125K	0.31%	73
2022 Q2	$5.26M	Buy	54,000 +8,760	+19%	+$808K	0.28%	89
2022 Q1	$4.24M	Buy	+45,240	New	+$3.83M	0.18%	124
2021 Q4	–	Sell	-1,405	Closed	-$135K	–	353
2021 Q3	$135K	Hold	1,405	–	–	0.01%	307
2021 Q2	$137K	Hold	1,405	–	–	﹤0.01%	314
2021 Q1	$137K	Sell	1,405 -1,775	-56%	-$186K	﹤0.01%	312
2020 Q4	$305K	Hold	3,180	–	–	0.01%	299
2020 Q3	$306K	Sell	3,180 -11,250	-78%	-$1.3M	0.01%	297
2020 Q2	$1.76M	Sell	14,430 -43,542	-75%	-$4.81M	0.08%	189
2020 Q1	$5.02M	Sell	57,972 -35,995	-38%	-$3.52M	0.3%	101
2019 Q4	$10.1M	Sell	93,967 -10,058	-10%	-$1.05M	0.4%	70
2019 Q3	$9.37M	Buy	+104,025	New	+$9.72M	0.38%	92
2019 Q1	–	Sell	-15,775	Closed	-$1.13M	–	387
2018 Q4	$1.13M	Sell	15,775 -30,890	-66%	-$2.96M	0.05%	257
2018 Q3	$5.74M	Buy	46,665 +4,195	+10%	+$476K	0.16%	184
2018 Q2	$4.17M	Sell	42,470 -3,480	-8%	-$312K	0.13%	209
2018 Q1	$3.81M	Buy	45,950 +16,330	+55%	+$1.38M	0.12%	214
2017 Q4	$2.3M	Buy	+29,620	New	+$2.02M	0.07%	251